TLX · Telix Pharmaceuticals Limited
$10.32
+1.84% last session
End-of-day data · updated 2026-07-24
Market cap
$4B
Enterprise value
$4B
Trailing P/E
—
Forward P/E
36.5
Dividend yield
—
Beta
0.63
Avg volume
0M
Employees
1K
2D change
1.84%
5D change
0.48%
10D change
-4.63%
30D change
-3.58%
60D change
10.98%
MTD change
-11.23%
YTD change
40.32%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TLX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-07
Latest call per bank · past 12 months
Citigroup
Buy$22.00
+113.2% vs priceUBS
Buy$20.00
+93.8% vs priceJP Morgan
Neutral$0.00
-100.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-07 | Citigroup | Maintains | Buy | $22.50 → $22.00 |
| 2026-07-07 | HC Wainwright & Co. | Reiterates | Buy | $20.00 |
| 2026-07-06 | Wedbush | Reiterates | Outperform | $22.00 |
| 2026-04-13 | Wedbush | Reiterates | Outperform | $22.00 |
| 2026-04-13 | HC Wainwright & Co. | Reiterates | Buy | $20.00 |
| 2026-04-07 | Wedbush | Reiterates | Outperform | $22.00 |
| 2026-04-07 | HC Wainwright & Co. | Reiterates | Buy | $20.00 |
| 2026-02-24 | Citigroup | Maintains | Buy | $22.00 → $22.50 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 47 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.4% above the 50-day MA ($10.36).
- Price vs 200-day MA: Trading 13.0% above the 200-day MA ($9.30).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.15) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($6.41) and high ($14.58).
TLX Price Chart
Loading chart for TLX…
Fundamentals
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen; and Regeneron Pharmaceuticals, Inc. for the development of radiopharmaceutical therapies and the joint development and commercialization of oncology programs. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$120B 4.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$68B -15.3% YTD
ARGX
argenx SE
$58B 10.0% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -32.4% YTD
ONC
BeOne Medicines Ltd.
$34B 7.6% YTD
RPRX
Royalty Pharma plc
$34B 54.2% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.